| HLA-DQB1* 03: 01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors H Ujiie, K Muramatsu, T Mushiroda, T Ozeki, H Miyoshi, H Iwata, ... The Journal of investigative dermatology 138 (5), 1201-1204, 2018 | 120 | 2018 |
| IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function C Montemurro, H Nomoto, L Pei, VS Parekh, KE Vongbunyong, ... Nature communications 10 (1), 2679, 2019 | 78 | 2019 |
| Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy C Yamamoto, H Miyoshi, K Ono, H Sugawara, R Kameda, M Ichiyama, ... Endocrine journal 63 (6), 589-596, 2016 | 64 | 2016 |
| Activation of the HIF1α/PFKFB3 stress response pathway in beta cells in type 1 diabetes H Nomoto, L Pei, C Montemurro, M Rosenberger, A Furterer, G Coppola, ... Diabetologia 63, 149-161, 2020 | 60 | 2020 |
| A comparison of the effects of the GLP-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial Sapporo … H Nomoto, H Miyoshi, T Furumoto, K Oba, H Tsutsui, A Miyoshi, T Kondo, ... PloS one 10 (8), e0135854, 2015 | 56 | 2015 |
| A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes … H Nomoto, H Miyoshi, H Sugawara, K Ono, S Yanagiya, M Oita, ... Diabetology & Metabolic Syndrome 9, 1-9, 2017 | 43 | 2017 |
| Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial T Takase, A Nakamura, C Yamamoto, H Nomoto, A Miya, M Dannoura, ... Journal of Diabetes Investigation 10 (3), 699-705, 2019 | 42 | 2019 |
| A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: Sapporo Athero-Incretin Study 1 (SAIS1) H Nomoto, H Miyoshi, T Furumoto, K Oba, H Tsutsui, A Inoue, T Atsumi, ... PloS one 11 (10), e0164255, 2016 | 41 | 2016 |
| The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3) N Kitao, H Miyoshi, T Furumoto, K Ono, H Nomoto, A Miya, C Yamamoto, ... Cardiovascular Diabetology 16 (1), 125, 2017 | 37 | 2017 |
| Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus A Miyoshi, S Nagai, M Takeda, T Kondo, H Nomoto, H Kameda, A Hirai, ... Journal of diabetes investigation 4 (3), 326-329, 2013 | 34 | 2013 |
| Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone KY Cho, A Nakamura, K Omori, T Takase, A Miya, K Yamamoto, ... Journal of Diabetes Investigation 12 (7), 1272-1277, 2021 | 33 | 2021 |
| Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice K Omori, A Nakamura, H Miyoshi, K Takahashi, N Kitao, H Nomoto, ... Metabolism 98, 27-36, 2019 | 33 | 2019 |
| Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus C Yamamoto, H Miyoshi, Y Fujiwara, R Kameda, M Ichiyama, H Nomoto, ... Endocrine journal 63 (1), 53-60, 2016 | 31 | 2016 |
| Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages K Takahashi, A Nakamura, H Miyoshi, H Nomoto, N Kitao, K Omori, ... Scientific reports 8 (1), 6864, 2018 | 28 | 2018 |
| IAPP-induced beta cell stress recapitulates the islet transcriptome in type 2 diabetes M Blencowe, A Furterer, Q Wang, F Gao, M Rosenberger, L Pei, ... Diabetologia 65, 173-187, 2022 | 24 | 2022 |
| Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea K Omori, H Nomoto, A Nakamura, T Takase, KY Cho, K Ono, N Manda, ... Journal of Diabetes Investigation 10 (2), 367-374, 2019 | 23 | 2019 |
| Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β-Cell Mass in db/db Mice K Omori, A Nakamura, H Miyoshi, Y Yamauchi, S Kawata, K Takahashi, ... Diabetes 70 (4), 917-931, 2021 | 19 | 2021 |
| Successful management of a patient with active Cushing’s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia A Yuno, Y Kenmotsu, Y Takahashi, H Nomoto, H Kameda, KY Cho, ... Endocrine Journal 68 (4), 477-484, 2021 | 17 | 2021 |
| Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment A Miya, A Nakamura, T Handa, H Nomoto, H Kameda, KY Cho, S Nagai, ... Journal of diabetes investigation 12 (5), 738-746, 2021 | 16 | 2021 |
| Inhibition of small Maf function in pancreatic β-cells improves glucose tolerance through the enhancement of insulin gene transcription and insulin secretion H Nomoto, T Kondo, H Miyoshi, A Nakamura, Y Hida, K Yamashita, ... Endocrinology 156 (10), 3570-3580, 2015 | 16 | 2015 |
Kyu Yong ChoHokkaido University在 med.hokudai.ac.jp 的电子邮件经过验证
